reports
Journey Medical Corporation Appoints Joseph Benesch as Chief Financial...
Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer SCOTTSDALE, Ariz., May 01, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the appointment of Joseph M. Benesch as Chief Financial Officer, effective April 26, 2024. Mr. Benesch had served as the Company’s Int...
Monolithic Power Systems Announces Results for the First Quarter Ended...
Monolithic Power Systems Announces Results for the First Quarter Ended March 31, 2024 KIRKLAND, Wash., May 01, 2024 (GLOBE NEWSWIRE) -- Monolithic Power Systems, Inc. (“MPS”) (Nasdaq: MPWR), a fabless global company that provides high-performance, semiconductor-based power electronics solutions, today announced financial results for the quarter ended March 31, 2024. Revenue was $457.9 million for the quarter ended March 31, 2024, a 0.9% increase from $454.0 million for the quarter ended December 31, 2023 and a 1.5% increase from $451.1 million for the quarter ended March 31, 2023. GAA...
Galecto Announces First Patient Dosed in an Investigator-Initiated Pha...
Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab An NCI-supported Phase 2 investigator-initiated trial at the Providence Cancer Institute in Portland, Oregon, has enrolled its first patient in a study exploring the combination of pembrolizumab (Keytruda®) and Galecto’s GB1211, an oral galectin-3 inhibitor, in patients with metastatic melanoma and head and neck squamous cell carcinoma BOSTON, May 01, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the devel...
Enovix Announces First Quarter 2024 Financial Results
Enovix Announces First Quarter 2024 Financial Results FREMONT, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- (“Enovix”) (Nasdaq: ENVX), a global high-performance battery company, announced today financial results for first quarter 2024, which included the summary below from its President and CEO, Dr. Raj Talluri. Fellow Shareholders, In the first quarter of 2024 we made tremendous progress toward readying Fab2 in Malaysia to begin production while closely collaborating with leading customers ahead of shipping first samples of our breakthrough EX-1M battery. Our recent highlights include: ...
FormFactor, Inc. Reports 2024 First Quarter Results
FormFactor, Inc. Reports 2024 First Quarter Results Reports Q1 Revenue Near the Top-End of the Outlook Range, Sees Significant Step-Up in Demand in Q2’24 LIVERMORE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- FormFactor, Inc. (Nasdaq: FORM) today announced its financial results for the first quarter of fiscal 2024 ended March 30, 2024. Quarterly revenues were $168.7 million, an increase of 0.3% compared to $168.2 million in the fourth quarter of fiscal 2023, and an increase of 0.8% from $167.4 million in the first quarter of fiscal 2023. Revenue near the top-end of the outlook range; no...
NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement
NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement EDINBURGH, United Kingdom, May 01, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), (“NuCana” or the “Company”), announced that it has received a written notification (the “Notification Letter”) from the Listing Qualifications Department of the Nasdaq Stock Market, LLC (“Nasdaq”) informing the Company that it has regained compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”) and the matter is closed. As announced on May...
LENZ Therapeutics to Report First Quarter Financial Results and Busine...
LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024 SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, today announced it will host a webcast on Wednesday, May 8, 2024 at 4:30 p.m. ET to report its first quarter 2024 financial results and provide a business update. The live webcast can be accessed and on the LENZ...
Enovix Reaches Development Agreement with a Leading Smartphone OEM
Enovix Reaches Development Agreement with a Leading Smartphone OEM FREMONT, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- (“Enovix”) (Nasdaq: ENVX), a global high-performance battery company, today announced it has reached a development agreement with one of the top five smartphone OEMs in the world by unit volume. “We are thrilled to announce we have advanced our engagement further with one of our top customers by reaching a formal development agreement, underscoring the value and competitive advantage our silicon batteries can provide to the next generation of smartphones, beginning with E...
MISTRAS Announces First Quarter 2024 Results
MISTRAS Announces First Quarter 2024 Results Q1 2024 Revenue of $184.4 million, up 9.8% from the prior year period; highest Q1 Revenue since 2018 Q1 2024 Net Income of $1.0 million, reflecting an improvement from a net loss of $5.0 million in the prior year period Q1 2024 Adjusted EBITDA (non-GAAP) of $16.2 million compared to $10.4 million in the prior year period, up 55.1%; highest Q1 result historically PRINCETON JUNCTION, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- MISTRAS Group, Inc. (MG: NYSE), a leading "one source" multinational provider of integrated technology-enabled asset protec...
Qorvo® Announces Fiscal 2024 Fourth Quarter Financial Results
Qorvo® Announces Fiscal 2024 Fourth Quarter Financial Results GREENSBORO, N.C., May 01, 2024 (GLOBE NEWSWIRE) -- Qorvo® (Nasdaq:QRVO), a leading global provider of connectivity and power solutions, today announced financial results for the Company’s fiscal 2024 fourth quarter ended March 30, 2024. Strategic Highlights Grew quarterly revenue 49% year-over-year and exceeded the mid-point of revenue guidance by $16 millionCompleted acquisition of Anokiwave, a leading supplier of high-performance silicon integrated circuits for intelligent active array antennas for Defense, SATCOM, ...
Avis Budget Group Reports First Quarter Results
Avis Budget Group Reports First Quarter Results PARSIPPANY, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ: CAR) announced financial results for first quarter 2024 today. We ended the quarter with revenues of $2.6 billion, driven by strong travel demand. Net loss was $113 million and our Adjusted EBITDA1 was $12 million. Our liquidity position at the end of the quarter was approximately $0.7 billion, with an additional $3.8 billion of fleet funding capacity. We have well-laddered corporate debt, and after giving effect to our euro note repayment in April 2024...
Energy Recovery Reports its First Quarter 2024 Financial Results
SAN LEANDRO, Calif.--(BUSINESS WIRE)-- Energy Recovery, Inc. (Nasdaq:ERII) (“Energy Recovery” or the “Company”) today announced its financial results for the first quarter ended March 31, 2024. First Quarter Highlights Revenue of $12.1 million, which is in-line with our February 2024 guidance. Gross margin of 59.0%, a decrease of 190 bps, as compared to Q1’2023, due primarily to higher manufacturing costs and an increase in inventory scrap. Operating expenses of $18.1 million, an increase of 11%, as compared to Q1’2023, due primarily to increased investments within sales and marketi...
OTC Markets Group Announces First Quarter 2024 Earnings Conference Cal...
OTC Markets Group Announces First Quarter 2024 Earnings Conference Call and Webcast NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- (OTCQX: OTCM) today announced it will report its financial results for the first quarter ended March 31, 2024, after the close of the U.S. capital markets on Wednesday, May 8, 2024. In addition, OTC Markets Group will host a conference call and webcast on Thursday, May 9, 2024, at 8:30 a.m. eastern time, during which management will discuss the financial results in further detail. Webcast:The conference webcast and management presentation can be accessed at t...
Metagenomi to regain full development rights to its wholly-owned base ...
Metagenomi to regain full development rights to its wholly-owned base editing and RIGS systems Enhances strategic flexibility and control of key gene editing technologies and programs EMERYVILLE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today announced it has regained full global rights to research, develop, manufacture, and commercialize its wholly-owned gene editing technologies,...
Skyward Specialty Insurance Group Reports First Quarter 2024 Results
Skyward Specialty Insurance Group Reports First Quarter 2024 Results HOUSTON, May 01, 2024 (GLOBE NEWSWIRE) -- Skyward Specialty Insurance Group, Inc. (Nasdaq: SKWD) (“Skyward Specialty” or the “Company”) today reported first quarter 2024 net income of $36.8 million, or $0.90 per diluted share, compared to $15.6 million, or $0.42 per diluted share. for the same 2023 period. Adjusted operating income(1) for the first quarter of 2024 was $31.0 million, or $0.75 per diluted share, compared to $15.5 million, or $0.42 per diluted share, for the same 2023 period. Highlights for the quarter in...
Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skinc...
Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare Elevai Labs established two subsidiaries: Elevai Biosciences, Inc., and Elevai Skincare, Inc.Elevai Biosciences will focus on acquiring and developing biopharmaceutical technologies with initial focus on the development of EL-22 and EL-32, the lead assets targeting indications associated with obesity.Elevai Skincare will continue commercializing exosome skincare technologies for the medical dispensed skincare market. NEWPORT BEACH, Calif.,...
- ABGSC Construct. & Real Estate Research
- Fredrik Stensved
- Markus Henriksson
- Viktor Stenlöf
- Chris Turner
- James Knightley
- Padhraic Garvey
- CFA
Fed holds policy steady: rate hikes remain “unlikely” despite lack of ...
The Federal Reserve left its policy rate unchanged and argued its policy stance is "in a good place", but officials are concerned about the recent lack of progress on inflation. Rate hikes remain unlikely, but the Fed is prepared to leave interest rates at current levels until that progress is achieved or the jobs market clearly weakens
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.